Physician profile
Eleonora Fedonenko
NPI 1790721850
$3,109.02
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $354 · 2021: $444 · 2022: $392 · 2023: $439 · 2024: $532 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.11 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $437.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.04 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $394.08 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $191.32 | 2019-2023 | Belsomra, Verquvo, Segluromet |
| Allergan, INC. | $187.83 | 2019-2022 | |
| Astellas Pharma US INC | $174.25 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $158.66 | 2022-2023 | |
| Amgen INC. | $88.48 | 2023-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $87.96 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.21 | 2019-2025 | Trulance, Xifaxan |
| Kowa Pharmaceuticals America, INC. | $62.33 | 2019-2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $53.05 | 2019-2021 | |
| Novo Nordisk INC | $48.56 | 2019-2025 | Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $47.76 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.80 | 2020-2022 | |
| Galderma Laboratories, L.P. | $42.50 | 2022-2023 | |
| Eisai INC. | $39.74 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $30.97 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $26.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleonora Fedonenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.